TY - JOUR
T1 - Discovery of New Broad-Spectrum Anti-Infectives for Eukaryotic Pathogens Using Bioorganometallic Chemistry
AU - Lin, Yan
AU - Jung, Hyeim
AU - Bulman, Christina A.
AU - Ng, James
AU - Vinck, Robin
AU - O’Beirne, Cillian
AU - Zhong, Shuai
AU - Moser, Matthew S.
AU - Tricoche, Nancy
AU - Peguero, Ricardo
AU - Li, Robert W.
AU - Urban, Joseph F.
AU - Le Pape, Patrice
AU - Pagniez, Fabrice
AU - Moretto, Marco
AU - Weil, Tobias
AU - Lustigman, Sara
AU - Cariou, Kevin
AU - Mitreva, Makedonka
AU - Sakanari, Judy A.
AU - Gasser, Gilles
N1 - Publisher Copyright:
© 2023 American Chemical Society.
PY - 2023/12/14
Y1 - 2023/12/14
N2 - Drug resistance observed with many anti-infectives clearly highlights the need for new broad-spectrum agents to treat especially neglected tropical diseases (NTDs) caused by eukaryotic parasitic pathogens, including fungal infections. Herein, we show that the simple modification of one of the most well-known antifungal drugs, fluconazole, with organometallic moieties not only improves the activity of the parent drug but also broadens the scope of application of the new derivatives. These compounds were highly effective in vivo against pathogenic fungal infections and potent against parasitic worms such as Brugia, which causes lymphatic filariasis and Trichuris, one of the soil-transmitted helminths that infects millions of people globally. Notably, the identified molecular targets indicate a mechanism of action that differs greatly from that of the parental antifungal drug, including targets involved in biosynthetic pathways that are absent in humans, offering great potential to expand our armamentarium against drug-resistant fungal infections and neglected tropical diseases (NTDs) targeted for elimination by 2030.
AB - Drug resistance observed with many anti-infectives clearly highlights the need for new broad-spectrum agents to treat especially neglected tropical diseases (NTDs) caused by eukaryotic parasitic pathogens, including fungal infections. Herein, we show that the simple modification of one of the most well-known antifungal drugs, fluconazole, with organometallic moieties not only improves the activity of the parent drug but also broadens the scope of application of the new derivatives. These compounds were highly effective in vivo against pathogenic fungal infections and potent against parasitic worms such as Brugia, which causes lymphatic filariasis and Trichuris, one of the soil-transmitted helminths that infects millions of people globally. Notably, the identified molecular targets indicate a mechanism of action that differs greatly from that of the parental antifungal drug, including targets involved in biosynthetic pathways that are absent in humans, offering great potential to expand our armamentarium against drug-resistant fungal infections and neglected tropical diseases (NTDs) targeted for elimination by 2030.
UR - http://www.scopus.com/inward/record.url?scp=85179601493&partnerID=8YFLogxK
U2 - 10.1021/acs.jmedchem.3c01333
DO - 10.1021/acs.jmedchem.3c01333
M3 - Article
C2 - 38009931
AN - SCOPUS:85179601493
SN - 0022-2623
VL - 66
SP - 15867
EP - 15882
JO - Journal of Medicinal Chemistry
JF - Journal of Medicinal Chemistry
IS - 23
ER -